Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19... see more

TSXV:VXL - Post Discussion

Vaxil Bio Ltd > From Bill & Melinda Gates Foundation .......
View:
Post by bligicka on Jan 02, 2021 10:52am

From Bill & Melinda Gates Foundation .......

In fact, this announcement brings the Gates Foundation’s total contribution towards fighting the pandemic to $1.75 billion, and much of it has gone towards the production and procurement of crucial medical supplies. (The breakdown is visualized above; some of the funding, including today’s commitment, comes in the form of new direct grants; another tranche is repurposed funding from elsewhere in our budget, while still more is not direct funding at all; it’s in the form of loans and other financing measures. You can read more about our sources of funding here).

It’s also important to point out that there is not a hard break between the scientific phase of the fighting the pandemic and this new, more logistical one. In 2021, R&D funding will still be needed for new drugs, vaccines, and tests, in part because some of these initial ones aren’t ideally suited for low-income nations. The Pfizer vaccine, for instance, needs to be kept at sub-zero temperatures, which will be very difficult when transporting it to very rural areas. Our foundation will keep funding innovation.

Comment by bigbanktheory on Jan 02, 2021 11:13am
Blig, gates is with AGN, correct me if I am wrong. I've been flipping agn for a while now. It hit 54 cents a short while ago. I never thought it would come down to .185 ever again, but it did. Reloaded...
Comment by bligicka on Jan 02, 2021 11:34am
The Gates foundation has funded $1.75 Billion, not sure where all that cash went but I know Vaxil didn't get a penny of it ....I'm just pointing out the money is out there to fund inovative projects such as Vaxil's Oral Vaccine experiment...... this could actually put Vaxil on the radar of Big Pharma ....Vaxil needs to form a partnership quickly as they can't do this alone !!!!
Comment by bligicka on Jan 03, 2021 9:37am
Now that David has confirmed the companies direction moving forward on his latest video its safe to say funding from Bill Gates will come.... Vaxil meets all the Gates Foundation requirements for funding ..... A inexpensive oral vaccine is a game changer for Africa and Latin America  ....... I expect things will start to move quickly for Vaxil this year !!!
Comment by bligicka on Jan 03, 2021 10:05am
I wonder if Bill has called David or vice versa.......I'm sure Vaxil is under Gates Foundation radar !!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities